December 17, 2019

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

GDC-0994 had an acceptable safety profile and pharmacodynamic effects were observed by FDG-PET and in serial tumor biopsies. Single-agent activity was observed in 2 patients with BRAF-mutant colorectal cancer.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Varga et al. (Tue,) studied this question.

synapsesocial.com/papers/69dd4adb7d97b7e86940c9df https://doi.org/https://doi.org/10.1158/1078-0432.ccr-19-2574

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR2012 · 2,063 citations
2Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics2010 · 82 citations
3Abstract CT107: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors2017 · 11 citations
4Targeting RAS signalling pathways in cancer therapy2003 · 3,246 citations
5Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma2010 · 1,823 citations

Preguntar a la IA

Me gusta

Guardar